YARW
What one share of Yarrow Bioscience holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need.
Yarrow Bioscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.56 |
|---|---|
| Profit | −$21.82 |
| Cash and investments | $34.30 |
| Debt | $0.00 |
| Book value | $33.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $27.03 | −$564.17 | $1.24 | −$92.08 | — | −$1,115 |
| 2017 | $179.40 | −$1,138 | $1.06 | −$1,106 | — | $2,589 |
| 2021 | $16.28 | −$1,282 | $0.00 | −$985.78 | — | $816.99 |
| 2022 | $7.49 | −$364.25 | — | −$458.25 | — | $483.05 |
| 2023 | $2.06 | −$138.48 | $0.00 | −$123.34 | — | $314.69 |
| 2024 | $0.59 | −$46.77 | $0.14 | −$40.02 | — | — |
| 2025 | $0.67 | −$30.96 | $0.00 | −$38.73 | — | $41.66 |